Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.16	$1.21	$0.86 ▼ $3.78	$257.38M	0.35	5.91 million shs	1.63 million shs
GNTA Genenta Science	$3.52 +0.9%	$3.59	$2.74 ▼ $7.28	$63.83M	0.62	5,984 shs	1,370 shs
LXEO Lexeo Therapeutics	$4.89 +4.9%	$4.41	$1.45 ▼ $11.96	$251.65M	1.36	390,104 shs	241,631 shs
PBYI Puma Biotechnology	$5.18 +3.8%	$3.81	$2.22 ▼ $6.07	$251.35M	1.3	926,512 shs	639,511 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+10.48%	-22.67%	+1.75%	-58.57%
GNTA Genenta Science	+0.72%	+3.23%	-7.59%	-18.61%	-13.73%
LXEO Lexeo Therapeutics	+4.94%	+2.30%	+18.40%	+78.47%	-56.76%
PBYI Puma Biotechnology	+3.81%	+1.77%	+57.93%	+53.71%	+95.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.667 of 5 stars	3.4	3.0	1.8	2.5	0.6
GNTA Genenta Science	2.7519 of 5 stars	3.5	3.0	3.8	1.7	0.0
LXEO Lexeo Therapeutics	2.536 of 5 stars	3.5	1.0	3.1	2.5	0.6
PBYI Puma Biotechnology	4.0778 of 5 stars	3.5	1.0	2.9	4.2	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	627.97% Upside
GNTA Genenta Science	3.00	Buy	$25.00	610.23% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$15.33	213.57% Upside
PBYI Puma Biotechnology	3.00	Buy	$7.00	35.14% Upside

Current Analyst Ratings Breakdown

Latest GNTA, PBYI, LXEO, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $15.00
8/15/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $9.00
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/31/2025	LXEO Lexeo Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	12,869.04	N/A	N/A	$1.55 per share	0.75
GNTA Genenta Science	N/A	N/A	N/A	N/A	$0.74 per share	N/A
LXEO Lexeo Therapeutics	$650K	406.25	N/A	N/A	$2.56 per share	1.91
PBYI Puma Biotechnology	$230.50M	1.13	$0.88 per share	5.86	$2.08 per share	2.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.11	N/A	N/A	N/A	N/A	-55.99%	-42.75%	11/6/2025 (Estimated)
GNTA Genenta Science	-$9.64M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	-$98.33M	-$3.26	N/A	N/A	N/A	N/A	-94.65%	-73.36%	11/12/2025 (Estimated)
PBYI Puma Biotechnology	$30.28M	$0.98	5.29	13.63	N/A	20.38%	53.15%	23.51%	11/6/2025 (Estimated)

Latest GNTA, PBYI, LXEO, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	LXEO Lexeo Therapeutics	-$0.64	-$0.60	+$0.04	-$0.60	N/A	N/A
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	8.92	8.92
GNTA Genenta Science	N/A	6.89	6.89
LXEO Lexeo Therapeutics	N/A	4.43	4.43
PBYI Puma Biotechnology	0.10	1.73	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
GNTA Genenta Science	15.13%
LXEO Lexeo Therapeutics	60.67%
PBYI Puma Biotechnology	61.29%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
GNTA Genenta Science	28.99%
LXEO Lexeo Therapeutics	5.30%
PBYI Puma Biotechnology	23.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	221.88 million	192.59 million	Optionable
GNTA Genenta Science	7	18.29 million	12.99 million	Not Optionable
LXEO Lexeo Therapeutics	58	54.00 million	51.14 million	Not Optionable
PBYI Puma Biotechnology	200	50.37 million	38.64 million	Optionable

GNTA, PBYI, LXEO, and ALLO Headlines

Recent News About These Companies

Puma Biotechnology (NASDAQ:PBYI) Upgraded to Buy at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Upgraded by Wall Street Zen to Buy Rating

August 18, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Boosts Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)

August 16, 2025 | marketbeat.com

Additional Considerations Required While Assessing Puma Biotechnology's (NASDAQ:PBYI) Strong Earnings

August 15, 2025 | finance.yahoo.com

Puma Biotechnology Reports Strong Q2 2025 Earnings

August 13, 2025 | msn.com

Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT

August 12, 2025 | msn.com

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

August 12, 2025 | zacks.com

Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?

August 12, 2025 | zacks.com

Results: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

August 10, 2025 | finance.yahoo.com

Puma Biotechnology (NASDAQ:PBYI) Downgraded to Hold Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call Transcript

August 9, 2025 | msn.com

Mackenzie Financial Corp Acquires 79,060 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

August 9, 2025 | marketbeat.com

PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues

August 8, 2025 | zacks.com

Puma (PBYI) Q2 Revenue Rises 11%

August 8, 2025 | fool.com

Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Puma Biotechnology (NASDAQ:PBYI) shareholders have endured a 70% loss from investing in the stock five years ago

August 2, 2025 | finance.yahoo.com

Puma Biotechnology (PBYI) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200-Day Moving Average - Here's What Happened

July 30, 2025 | marketbeat.com

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results

July 24, 2025 | businesswire.com

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $90,990.00 in Stock

July 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA, PBYI, LXEO, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.16 0.00 (0.00%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$1.15 -0.01 (-0.52%)

As of 08/26/2025 06:53 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Genenta Science NASDAQ:GNTA

$3.54 +0.05 (+1.58%)

As of 08/26/2025 04:00 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Lexeo Therapeutics NASDAQ:LXEO

$4.89 +0.23 (+4.94%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$4.88 -0.01 (-0.20%)

As of 08/26/2025 05:29 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Puma Biotechnology NASDAQ:PBYI

$5.18 +0.19 (+3.81%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$5.29 +0.11 (+2.12%)

As of 08/26/2025 07:41 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time